OTCMARKETS... RXMD NEWS - PROFILE - FILINGS
: http://www.otcmarkets.com/stock/RXMD/news http://www.otcmarkets.com/stock/RXMD/profile http://www.otcmarkets.com/stock/RXMD/filings CEO INTERVIEW https://www.youtube.com/embed/P-YQDkMS4y8
INVESTOR PAGE FROM WEBSITE http://progressivecareus.com/investor/
Company increased revenue from $13,642,704
in 2015 to $ 18,318,567
in 2016. That's a 34%
increase; Assets increased from $1,361,052 in 2015 to $2,610,167 in 2016
. That's a 92% increase in assets (while liabilities increased only 63%); Profit went from the 2015 net loss of $1,219,359 to the 2016 net income of $209,319
, bringing the Total Stockholders' Deficit from (3,419,896) to (3,210,577);
< $18M+ in revenue, PROFITABLE, growing 34%/yr... and only $3.2M in TOTAL deficit --- absolutely fantastic, almost unheard of in penny stocks --- if you let anyone tell you that's looks bad, well, I'm sorry you don't read financial statements much and you therefore can't get comfortable with holding stocks for more than a day or a week (because you have NO CLUE what you're holding) > And cash on hand went from $289,677 on Dec 31, 2015 to $816,220 on Dec 31, 2016 - that's a lot of cash on hand!
It doesn't take much time to see in the financial statements and throughout the report that everything Shital has put in the PR's about the business expansion - physical expansion AND services expansion AND revenue-producing business entity expansion - is where the rest of the profit is going... right back into the business for growth!
Do I think it's possible for the business to grow revenue by another 34%? After growing 34% last year? And 21% in 2015? And 21% in 2014? SUBSTANTIAL GROWTH
year over year, quarter over quarter, and the greatest growth this past year and that was BEFORE any significant contribution could be made from the high-efficiency robotic dispensing and the physical expansion and improvements. So where did it come from? Could it be that the company spoke truthfully all of last year about the various services that have been added and the impact they're having for attracting more and more high-margin customers and health service 'partners' (doctors, clinics, etc)? No doubt.
So, no - I think the company can do not only 34% growth this year, but the potential is there for much more. Organically? Absolutely, the 34% to 40% range is clearly possible, if not probably. However, with the strength Progressive Care & PharmCo has now, it's only a matter of time before a significant M&A move is made, IMO. So I look for growth to be higher.
Now, considering that revenue has grown in a big way, cash on-hand is fantastic, the company has access to capital for even more rapid expansion or other growth activities... and the stock is actually down 50% from when the compared had significantly lower revenues and had yet to show NET PROFITABILITY... and we have just BEGUN to see the effect of the business expansion...
Looks to me like shorts and naysayers have some conflicts to resolve... quickly. I just don't think the market's going to sit back and keep letting the little people dictate this artificially low price anymore.
But that's just my opinion, I think everyone ought to learn how to read financial statements and sort real information from boilerplate legal safe harbor statements... and sort the wheat from the chaff when it comes to "opinions." It's called DD, and it pays off well for those who put a little effort into it - gives you a little peace of mind when you can hold a strong position and let your money do the work FOR you. In a BIG way! That $1 price that I wrote about a year ago? Looks to me like we're in for some real progress in that direction. How RXMD is going to get to $1
This is a 50x improvement over today's ~$0.02 share price. Do I think it will happen this year? Though some believe it's possible, I wouldn't bet the farm on it. Do I think it's very possible within the next 3-5 years? Absolutely! Here's how and why...
First, Progressive Care, Inc. (RXMD) is clearly undervalued, but the pps is correcting and will be reaching upward for 0.10+ before you know it. Organic growth and a handful of acquisitions - simply executing the strategic plan - will do the rest. I see RXMD as a serious buyout target in 2-3 years!
Large national pharmacy companies are fending off competition from mail-order prescription discounters, online pharmacies, wholesale retailers such as Costco and health clinics, among others:
• Dec 16, 2015 - CVS Health Corporation (NYSE:CVS) and Target Corporation (NYSE:TGT) announced today that CVS Health has completed the acquisition of Target's pharmacy and clinic businesses for approximately $1.9 billion.
• Oct 28, 2015 - Walgreens said on Tuesday that it will buy rival Rite Aid in a $17.2 billion deal that would whittle the nation's one-time mom-and-pop drug-store industry into two massive chains. Walgreens Boots Alliance, which operates the namesake drug store chain, said it is paying $9 per share in cash in a valuation that includes the assumption of debt. That reflects a 48% premium above Rite Aid's value at the close of trading Monday.
• Aug 19, 2015 - CVS Health Corp. (CVS - Analyst Report) has completed the acquisition of Ohio-based pharmacy services provider, Omnicare, for $12.7 billion, including a debt of $2.3 billion, well ahead of time. The buyout reflects the company’s foray into a new pharmacy distribution channel – the long-term specialty care market.
• From a 2010 article:
Omnicare has a rich history of growth through acquisitions, which has made it a dominant player in the industry. The company boasts a reasonably sound balance sheet and is well positioned with healthy cash flow, which it can use for further acquisitions, debt repayments and share repurchases. Omnicare is pursuing an aggressive acquisition strategy in fiscal 2010. The company agreed to buy institutional pharmacy businesses in July 2010 and is also in advanced negotiations for other acquisitions.
While the goliaths have been hammering away at acquisitions and consolidation in the broader pharmacy retail sales and services markets to maximize commodity-type margins, Progressive Care, Inc. (RXMD) has been quietly whittling away at a health services business model that focuses on a small but substantial piece of the very large pie. This piece of pie, however, concentrates on high-margin revenue derived from medications and services for an underserved segment of the market. Progressive Care specializes in the care and management of patients with special needs, long-term care needs, and including medications for infectious diseases.
As stated in the Open Letter to Shareholders, Progressive Care will continue to strengthen the successful PharmCo model by "adding business elements that cater to specific under-served markets and demographics." In doing so, Progressive Care raises the bar, creating a steeper barrier to entry for regional competition in existing markets. For example, Progressive Care will add a "closed-door pharmacy facility" to the existing PharmCo operation this year. It seems likely that this will be a nearby (near the existing PharmCo site) satellite pharmacy operation embedded in a long-term care or other health services facility in one of the underserved markets/demographics of focus.
As also stated in the Open Letter to Shareholders, Progressive Care "will also look for opportunities to expand the pharmacy through establishing new locations or through mergers/acquisitions with similarly positioned independent pharmacies," and "will seek licensures in additional states in order to begin positioning PharmCo as a national brand."
Progressive Care, Inc. (RXMD) has it in the game plan to grow revenue organically and to expand into other markets nationally through acquisitions.
The goliaths have it in their game plan to continue increasing shareholder value - indefinitely. As the pending market consolidation in the major pharmacy store and services sector is nearing completion, these companies will look to the next opportunities, especially those that offer higher gross margins. They will not be able to do this organically through existing infrastructure, as the services are much more specialized than what a discount pharmacy operation can profitably support. That is, it's simply not a good product mix. The only way they will be able to continue improving shareholder value at their historic rates is through acquisitions.
If you're trading on the OTCBB and you're new to RXMD, it would be a very smart move IMO to diversify your "investments" and take 10-20% of your funds and get a starting position in this stock for the long-haul growth toward this 40-50-60x gain opportunity over 3-5-7 years. Add when you can on any dips and stay long, and use other funds for flipping other penny stocks if that's something that appeals to you. Wanna retire young? This is a road map that's easy to read.
RXMD is a STABLE and GROWING company that is checking off all the right boxes...
Easy communication with management
Zero dilution in '16 in fact O/S reduced by 12M shares from 1/16 to 1/17
Price is over 50% below the 52 week high, and sales and profits have gone up 30% since then NOW IS THE ENTRY POINT At just 1X sales, this company is worth .053/share
$18.3M / 344M = .053 which is exactly where our 52 week high was, and after growing another 30% in Q1 '17 we can extrapolate value later this year at .068/share
2-4 yrs to MAXIMIZE PROFITS MUCH DD TAKEN FROM MONEYFORNUTHIN OFF THE MAIN BOARD